


Dihydroartemisinin

Chemical Properties

CAS No. :	71939-50-9
Formula:	C ₁₅ H ₂₄ O ₅
Molecular Weight:	284.35
Appearance:	no data available
Storage:	keep away from moisture
	Powder: -20°C for 3 years In solvent: -80°C for 1 year



Biological Description

Description	Dihydroartemisinin (Artemimol) is a metabolite of artemisinin.
Targets(IC50)	Apoptosis,NF-κB,Parasite,Autophagy
In vitro	Dihydroartemisinin (DHA) inhibits the growth of certain cancer cell lines and xenograft tumors such as leukemia, glioma, fibrosarcoma, and breast, cervical, ovarian, lung, oral and pancreatic cancer. DHA inhibits cell and tumor growth by modulating various tumor-suppressive pathways, such as inhibiting cell proliferation and inducing apoptosis through regulation of proliferation- and apoptosis-related proteins.DHA inhibits the proliferation and viability of cells in a dose-dependent manner and induces apoptosis.DHA-mediated cytotoxicity is tumor selective. The endoperoxide bridge of DHA is reportedly essential for its cytotoxicity because it reacts with intracellular ferrous iron to generate reactive oxygen species or carbon-centered radicals, leading to cytotoxicity[1].
In vivo	DHA significantly inhibited HCC cell growth in vitro and in vivo via inducing G2/M cell cycle arrest and apoptosis[2]. DHA has been shown in the rat whole embryo culture (WEC) to primarily affect primitive red blood cells (RBCs) causing subsequent tissue damage and dysmorphogenesis[3].
Cell Research	BxPc3-RFP cells (3.5×10 ⁴ cells/well) were seeded in poly D-lysine-coated black, μClear 96-well plates with 0.2 ml medium. After 24 h, the cells were treated with dimethyl sulfoxide (DMSO) (control) or different concentrations (2.5, 10, 40, or 80 μM) of DHA dissolved in DMSO for 24, 48, and 72 h. At each time point, the fluorescence intensity emitted from cells was measured. (Only for Reference)

Solubility Information

Solubility	Ethanol: 9 mg/mL (31.65 mM),Sonication is recommended. H ₂ O: < 1 mg/mL (insoluble or slightly soluble), 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5.2 mg/mL (18.29 mM),Suspension. DMSO: 8.13 mg/mL (28.57 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.5168 mL	17.584 mL	35.1679 mL
5 mM	0.7034 mL	3.5168 mL	7.0336 mL
10 mM	0.3517 mL	1.7584 mL	3.5168 mL
50 mM	0.0703 mL	0.3517 mL	0.7034 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Aung W, et al. Anticancer Res. 2011, 31(5):1549-1558.

Liu W, Zheng M, Zhang R, et al. RNF126-Mediated MRE11 Ubiquitination Activates the DNA Damage Response and Confers Resistance of Triple-Negative Breast Cancer to Radiotherapy. Advanced Science. 2022: 2203884.

Wang J, Zhang J, Guo Z, et al. Targeting HSP70 chaperones by rhein sensitizes liver cancer to artemisinin derivatives. Phytomedicine. 2023: 155156.

Zhang CZ, et al. Biochem Pharmacol. 2012, 83(9):1278-1289.

Longo M, et al. Reprod Toxicol. 2006, 22(4):797-810.

Hsu Y F, Kung F L, Huang T E, et al. Anticancer Activity and Molecular Mechanisms of an Ursodeoxycholic Acid Methyl Ester-Dihydroartemisinin Hybrid via a Triazole Linkage in Hepatocellular Carcinoma Cells. Molecules. 2023, 28(5): 2358.

Liu Y, Li H, Luo Z, et al. Artesunate, a new antimalarial clinical drug, exhibits potent anti-AML activity by targeting the ROS/Bim and TFRC/Fe2+ pathways. British Journal of Pharmacology. 2022

Md. Yusuf N, Azman A N, Abdul Aziz A A, et al. Evaluation of the binding interactions between Plasmodium falciparum Kelch-13 mutant recombinant proteins with artemisinin. PloS one. 2024, 19(8): e0306975.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286

E_mail: info@targetmol.com

Address: 36 Washington Street, Wellesley Hills, MA 02481